Submit a Release
Home
All
ESG
Health
Technology
Finance
Contributors
Sub Menu
Submit a Release
main-search-pop
Main menu
Leqembi® Pen subcutaneous formulation approved in Japan
Contributed by:
PR Newswire
Tags
BioArctic
More Like This
BLA for subcutaneous formulation of Leqembi® accepted in China
New clinical data on the Leqembi® subcutaneous autoinjector presented at AAIC® 2026 support similar efficacy and safety to IV formulation in early Alzheimer's disease
BLA for subcutaneous formulation of Leqembi® designated for Priority Review in China
FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer's disease
Leqembi® Iqlik™ (lecanemab-irmb) supplemental Biologics License Application regarding subcutaneous starting dose granted Priority Review by the US FDA
FDA accepts Biologics License Application for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US
Eisai initiates rolling Biologics License Application to US FDA for Leqembi® (lecanemab-irmb) for subcutaneous maintenance dosing
US FDA approves Leqembi® IQKLIK™ (lecanemab-irmb) subcutaneous injection for maintenance dosing for the treatment of early Alzheimer's disease
